185 related articles for article (PubMed ID: 31682164)
21. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
23. Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S
Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
[TBL] [Abstract][Full Text] [Related]
24. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
25. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
26. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Hematol Oncol; 2005 Mar; 23(1):34-40. PubMed ID: 16149106
[TBL] [Abstract][Full Text] [Related]
27. A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.
Wilhelm K; Yang D
J Oncol Pharm Pract; 2011 Jun; 17(2):91-103. PubMed ID: 20085962
[TBL] [Abstract][Full Text] [Related]
28. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
30. Initial therapy of chronic lymphocytic leukemia.
Eichhorst B; Cramer P; Hallek M
Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Molica S
BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
[TBL] [Abstract][Full Text] [Related]
32. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
33. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
34. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
[TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
Sharma S; Rai KR
Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
[TBL] [Abstract][Full Text] [Related]
36. Diagnosing and treating chronic lymphocytic leukemia in 2009.
Kaufman M; Rubin J; Rai K
Oncology (Williston Park); 2009 Nov; 23(12):1030-7. PubMed ID: 20017285
[TBL] [Abstract][Full Text] [Related]
37. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1787-800. PubMed ID: 17181492
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
39. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
40. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
